<DOC>
	<DOCNO>NCT01288339</DOCNO>
	<brief_summary>To estimate progression free survival subject treat panitumumab combination chemotherapy regimen oxaliplatin , 5-Fluorouracil ( 5-FU ) leucovorin ( FOLFOX ) first-line chemotherapy regimen subject metastatic colorectal cancer WT ( wild type ) KRAS accord IGFRp ( protein receptor insulin growth factor ) MMP-7 ( Matrilysin ) expression .</brief_summary>
	<brief_title>Study Assessing Potential Predictive Tumor Markers Metastatic Colorectal Cancer</brief_title>
	<detailed_description>By transactivation , phosphorylated insulin growth factor receptor I ( p-IGF-IR ) activate epidermal growth factor receptor ( EGFR ) . Matrilysin ( MMP-7 ) , activate IGF-IR ( insulin-like growth factor receptor ) degrade IGFBP-3 ( Insulin-like growth factor-binding protein 3 ) release IGF-I ( Insulin-like growth factor 1 ) . Concomitant expression MMP-7 p-IGF-IR ( use specific monoclonal antibody ( p-1316 ) recognize phosphorylated carboxy-terminal part IGF-IR ) ( DP ( Double Positivity ) ) correlate poor prognosis WT KRAS patient treat anti-EGFR antibody plus irinotecan.The primary objective trial estimate progression free survival ( PFS ) DP ( Double Positivity ) immunohistochemistry ( IHC ) expression patient wild-type KRAS mCRC ( metastatic colorectal cancer ) treat panitumumab mFOLFOX6 . Two group establish DP status ( MMP7+/p-IGF-IR+ vs. MMP7+/p-IGF-IR- , MMP7-/p-IGF-IR+ MMP7-/p-IGF-IR- ) . With power 80 % bilateral alpha level 0.05 , assume accrual period 12 month ( ) follow-up period 18 , 40 patient plan include group detect Hazard Ratio 2 . The median PFS DP group expect 6 total number expect event 56 . Secondary objective include disease control rate , duration response , time response survival accord DP status . Neither interim analysis multiple comparison adjustment planned.Treatment : Both group receive panitumumab 6 mg/kg mFOLFOX6 every 2 week . If patient progress 6 treatment continue panitumumab monotherapy disease progression .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Man woman ≥ 18 year . Competent comprehend , sign , date IECapproved ( Ethics Committee ) inform consent form Histologicallyconfirmed metastatic adenocarcinoma colon rectum investigator . Wild Type KRAS colorectal cancer determine designated Central Laboratory prior inclusion study primary tumor and/or least one metastasis . At least 1 unidimensionally measurable lesion least &gt; 10 mm spiral CT per modify RECIST criterion 1.1 . ( Response Evaluation Criteria In Solid Tumors ) Patients follow characteristic include : 1 . Recurrence adjuvant treatment 5fluorouracil/folinic acid capecitabine +/ radiotherapy diseasefree interval &gt; 6 month completion . 2 . Recurrence adjuvant treatment oxaliplatin +/ radiotherapy diseasefree interval &gt; 12 month 3 . De novo diagnosis disease . Eastern Cooperative Oncology Group performance status 0 1 . Life expectancy ≥ 3 month Adequate bone marrow function Adequate Hepatic metabolic function Adequate Renal function Magnesium &gt; LLN ( Lower limit Normal ) Patients receive prior systemic therapy treatment metastatic colorectal carcinoma . Prior antiEGFr antibody therapy ( eg , cetuximab ) treatment small molecule EGFr tyrosine kinase inhibitor ( eg , erlotinib ) EGFR signal transduction inhibitor . Patients resection metastatic disease Central nervous system/brain metastasis Prior malignant tumor last 5 year , except history basal cell carcinoma skin preinvasive cervical cancer . Unresolved toxicity prior systemic therapy , opinion investigator , qualify patient inclusion Presence peripheral neuropathy ( Common Toxicity Criteria ( CTC ) version 3.0 &gt; grade 1 ) , serious nonhealing wound , ulcer , bone fracture . Hormonal therapy , immunotherapy experimental approve proteins/antibodies ( eg , bevacizumab ) ≤ 30 day inclusion Significant cardiovascular disease include unstable angina myocardial infarction within 12 month initiate study treatment history ventricular arrhythmia . History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis baseline chest CT scan Treatment systemic infection within 14 day initiate study treatment Acute subacute intestinal occlusion /or active inflammatory bowel disease bowel disease cause chronic diarrhea ( define &gt; 4 loose stool per day ) . Known positive test human immunodeficiency virus infection , hepatitis C virus , chronic active hepatitis B infection Any investigational agent within 30 day enrollment Subject pregnant breast feeding Surgery ( exclude diagnostic biopsy central venous catheter placement ) and/or radiotherapy within 14 day prior inclusion study . Woman man childbearing potential consenting use adequate contraceptive precaution</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>